AB Science SA (AB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

AB Science SA (AB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH140692D
  • |
  • Pages: 77
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

AB Science SA (ABS) is a pharmaceutical company focused on discovery, development, and commercialization of protein kinase inhibitors. The company's lead compound Masitinib, is a orally administered tyrosine kinase inhibitor targeting mast cells and selected kinases, including c-Kit, PDGFR, and Lyn in several human indications such as oncology, inflammatory diseases, and central nervous system diseases. The company is commercializing its lead product candidate in human and veterinary medicine. ABS has also developed KIT816 for the treatment of aggressive mastocytosis, seminoma, and acute myeloid leukemia; and syk for rheumatoid arthritis, b-cell lymphoma, and others. The company has operations in France and the US. ABS is headquartered in Paris, France.

AB Science SA (AB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

AB Science SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AB Science SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AB Science SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AB Science SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AB Science SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

AB Science SA, Pharmaceuticals & Healthcare, Deal Details 11

Equity Offering 11

AB Science Raises USD20.5 Million in Private Placement of Shares 11

AB Science Raises USD16.2 Million in Private Placement of Shares 12

AB Science Raises USD8 Million in Public Offering of Shares 13

AB Science Raises USD13.5 Million in Private Placement of Shares 14

Debt Offering 16

AB Science Completes Private Placement Of Bonds Due 2019 For USD 13 Million 16

AB Science SA-Key Competitors 17

AB Science SA-Key Employees 18

AB Science SA-Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 19

Recent Developments 20

Financial Announcements 20

Oct 01, 2018: AB Science reports its revenues for the first half of 2018 20

Apr 30, 2018: AB Science reports its annual financials as of 31 December 2017 and provides an update on its activities 24

Aug 31, 2017: AB Science: Revenue Report For First Half of 30 June 2017 30

Aug 31, 2017: AB Science reports its revenue for the first half of 2017 34

May 01, 2017: AB Science Reports its Annual Financials as of 31 December 2016 and Provides an Update on its Activities 40

Product News 47

09/28/2017: AB Science announces that abstracts reporting on clinical and preclinical data of masitinib in the treatment of ALS, have been selected for presentation at 6 major international meetings during 2017 47

09/14/2017: AB Science announces that CHMP adopted a negative opinion for masitinib marketing authorization in indolent systemic mastocytosis after reassessment 50

05/28/2018: AB Science provides update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis 51

05/18/2017: AB Science Announces Refusal of the marketing authorisation for Masipro (masitinib) 52

05/17/2017: AB Science announces that CHMP has adopted a negative opinion for masitinib in indolent systemic mastocytosis, primarily due to GCP inspection findings 53

04/19/2018: AB Science announces that the CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis 55

03/22/2018: EPFL: Attacking lymphoma at the source 56

03/20/2017: AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis 57

Clinical Trials 59

Jan 04, 2018: AB Science announces that based on interim analysis, IDMC recommended the continuation of the masitinib phase 3 study in progressive multiple sclerosis with no requirement to increase the sample size 59

Nov 21, 2017: Preclinical data published in Nature Communications shows that masitinib is capable of counteracting resistance to oncology treatments, including gemcitabine 60

Oct 19, 2017: Preclinical data showing protective effect of masitinib on the peripheral nervous system in ALS published in the Journal of Clinical Investigation Insight 62

Jun 22, 2017: AB Science Presents Supportive Data from its Phase 3 Study in Severe Systemic Mastocytosis at the 22nd Congress of the European Hematology Association 64

May 18, 2017: AB Science Presents Phase 3 Data for Masitinib in Amyotrophic Lateral Sclerosis at the European Network For The Cure of ALS Annual Meeting 66

May 12, 2017: AB Science announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice standards 68

Mar 29, 2017: AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years 70

Mar 07, 2017: AB Science Announces That Frontiers In Aging Neuroscience Publishes A Comprehensive Review On The Future Potential Of Masitinib In Amyotrophic Lateral Sclerosis 71

Mar 06, 2017: AB Science announces completion of patient recruitment for phase 3 study in severe persistent asthma 72

Jan 09, 2017: AB Science announces publication in The Lancet of phase 3 clinical trial results demonstrating masitinib is effective and well tolerated in the treatment of adult patients with severe indolent systemic mastocytosis 73

Jan 03, 2017: New Preclinical Data Demonstrate That Masitinib Has An Unexpected Protective Effect On Muscles And Nerves In Amyotrophic Lateral Sclerosis 75

Appendix 77

Methodology 77

About GlobalData 77

Contact Us 77

Disclaimer 77

List of Figures

AB Science SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AB Science SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AB Science SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AB Science SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AB Science SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AB Science SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

AB Science SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AB Science SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

AB Science SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

AB Science SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AB Science SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AB Science SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AB Science SA, Deals By Therapy Area, 2012 to YTD 2018 9

AB Science SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

AB Science Raises USD20.5 Million in Private Placement of Shares 11

AB Science Raises USD16.2 Million in Private Placement of Shares 12

AB Science Raises USD8 Million in Public Offering of Shares 13

AB Science Raises USD13.5 Million in Private Placement of Shares 14

AB Science Completes Private Placement Of Bonds Due 2019 For USD 13 Million 16

AB Science SA, Key Competitors 17

AB Science SA, Key Employees 18

AB Science SA, Subsidiaries 19

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AB Science SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17833
Site License
USD 500 INR 35665
Corporate User License
USD 750 INR 53498

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com